• Total revenue of $783.2 million, up 56% from FY2023
• Adjusted EBITDA of $99.3 million, up 70% from FY2023
• Prepared for launch of 3 new products in 2025: TLX007-CDx, TLX101-CDx, and TLX250-CDx

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX) today announced its financial results for the year ended 31 December 2024. The company reported total revenue of $783.2 million, driven primarily by sales of Illuccix®, up 56% from $502.5 million in 2023, beating full year guidance. Telix delivered its second year of profitable growth, with adjusted EBITDA of $99.3 million, up 70% from the previous year. The company continued to invest in its growth strategy, including $194.6 million in R&D and $15.8 million in manufacturing and distribution infrastructure. Key achievements in 2024 included preparing for the launch of three new products - TLX007-CDx (Gozellix®), TLX101-CDx (Pixclara®), and TLX250-CDx (Zircaix®) - in 2025, while also increasing sales and market share for Illuccix®. Telix also expanded its late-stage therapeutic trials and advanced its next-generation pipeline. The company completed strategic acquisitions of ARTMS, IsoTherapeutics, and RLS (USA), Inc. to expand its global delivery infrastructure. Telix provided FY2025 revenue guidance of $1.18 billion to $1.23 billion, excluding revenue from products not yet approved.

Telix provides FY2025 revenue guidance of $1.18 billion to $1.23 billion (US$770 million to US$800 million). This guidance includes revenue from Illuccix (in jurisdictions with a marketing authorization) and 11 months of revenue from RLS (and excluding RLS revenue generated from Illuccix). Telix has also provided R&D expenditure guidance, expecting an increased investment range of 20% to 25% compared to FY2024.

Telix sees 2025 as a year of significant growth and evolution, with international business expansion, multiple product launches, and the integration of key infrastructure to further deliver on the company's mission to ensure global patient access.